Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis. [PDF]
PLoS ONE, 2013 BACKGROUND: Abciximab is a widely used adjunctive therapy for acute coronary syndrome (ACS). However, the effect of intracoronary (i.c.) administration of abciximab on cardiovascular events remains unclear when compared with intravenous (i.v.) therapy ...
Jie-Ning Wang +6 more
doaj +3 more sources
Development of Reference Intervals for the TEG 6s, a Point‐of‐Care Viscoelastic Assay, in Dogs [PDF]
Veterinary Clinical Pathology, Volume 54, Issue 3, Page 292-299, September 2025.ABSTRACT Background Thromboelastography (TEG) provides a global assessment of hemostasis and identifies patients with both hemorrhagic and thrombotic tendencies. Traditional TEG instruments, such as the TEG 5000 (Haemonetics), can be labor‐intensive and require specialized training to operate.
Ashley R. Wilkinson +2 more
wiley +2 more sources
Sustainable Practices in Anti‐VEGF Therapy: A 15‐Year Bibliometric Analysis of Ranibizumab for Age‐Related Macular Degeneration [PDF]
Journal of Ophthalmology, Volume 2025, Issue 1, 2025.Objective: A bibliometric analysis was performed in the domain of ranibizumab and age‐related macular degeneration (AMD) to delineate current trends in international research dynamics and to provide a visual representation of research hotspots and challenges associated with ophthalmic drugs over the past 15 years.
Li Xiaodong +6 more
wiley +2 more sources
Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents [PDF]
Blood Vessels, Thrombosis & Hemostasis: Mouse models, such as the intravital laser-induced model of thrombus formation, are commonly used for mechanistic and preclinical studies in thrombosis. However, their translational value is limited by species differences.
Alexander Dupuy +7 more
doaj +2 more sources
Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. [PDF]
, 1999 BACKGROUND: In patients with refractory unstable angina, the platelet glycoprotein IIb/IIIa-receptor antibody abciximab reduces the incidence of cardiac events before and during coronary angioplasty.
Adgey, J. (Jennifer) +9 more
core +4 more sources
Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing [PDF]
Clinical Pharmacology &Therapeutics, Volume 118, Issue 2, Page 470-479, August 2025.P2Y12 inhibitor selection involves numerous factors, including CYP2C19 genetics, since evidence demonstrates reduced clopidogrel efficacy in patients with decreased or no function CYP2C19 variants. In 2020, Indiana University health embedded interruptive clinical decision support (CDS) alerts in the electronic health record (EHR) to recommend ...
Ashley N. Springer +14 more
wiley +2 more sources
Comparison of Angioplasty with Stenting, with or without Abciximab, in Acute Myocardial Infarction [PDF]
New England Journal of Medicine, 2002 Gregg W. Stone +11 more
exaly +2 more sources
Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up [PDF]
European Heart Journal, 2007 David Antoniucci +2 more
exaly +2 more sources
A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel [PDF]
New England Journal of Medicine, 2004 Adnan Kastrati, Peter B Berger
exaly +2 more sources
Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. [PDF]
, 2017 Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size.
Akyol, Onat +6 more
core +8 more sources